Page last updated: 2024-09-03

mk 0663 and Blood Clot

mk 0663 has been researched along with Blood Clot in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (66.67)	29.6817
2010's	2 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cannon, CP; Combe, B; Connors, L; Curtis, S; Emery, P; Kaur, A; Laine, L; McCarthy, T; McLay, J; Swergold, G; Zerbini, C	1
Brune, K; Cannon, CP; Contant, CF; Curtis, SP; Jarolim, P; Kaur, A; Laine, L; Morrow, DA; Ren, F; Ruff, CT	1
Brater, DC; Cannon, CP; Curtis, SP; Gammaitoni, A; Kaur, A; Krum, H; Laine, L; Peloso, PM; Smugar, SS; Swergold, G; Wang, H; Weir, MR	1
Bingham, CO; Bird, S; Fitzgerald, BJ; Kremer, J; O'Brien, K; Rubin, BR; Ruoff, GE; Sebba, AI; Smugar, SS; Tershakovec, AM	1
Bolognese, JA; Cavanaugh, PF; Curtis, SP; Ko, AT; Reicin, AS	1
Einecke, D	1

Reviews

1 review(s) available for mk 0663 and Blood Clot

Article	Year
Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib. Current medical research and opinion, 2006, Volume: 22, Issue:12 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Osteoarthritis; Pyridines; Randomized Controlled Trials as Topic; Sulfones; Thrombosis	2006

Article

Year

Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.

Current medical research and opinion, 2006, Volume: 22, Issue:12

Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Osteoarthritis; Pyridines; Randomized Controlled Trials as Topic; Sulfones; Thrombosis

2006

Trials

3 trial(s) available for mk 0663 and Blood Clot

Article	Year
Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford, England), 2009, Volume: 48, Issue:4 Topics: Aged; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Emergencies; Etoricoxib; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Odds Ratio; Osteoarthritis; Pyridines; Safety; Sample Size; Sulfones; Thrombosis	2009
Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. Cardiovascular therapeutics, 2012, Volume: 30, Issue:6 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Blood Pressure; Body Weight; Comorbidity; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Etoricoxib; Female; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Pyridines; Racial Groups; Risk Assessment; Sulfones; Thrombosis	2012
Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford, England), 2007, Volume: 46, Issue:3 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Etoricoxib; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Male; Middle Aged; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Pyrazoles; Pyridines; Severity of Illness Index; Sulfonamides; Sulfones; Thrombosis; Treatment Outcome	2007

Other Studies

2 other study(ies) available for mk 0663 and Blood Clot

Article	Year
Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. The Journal of rheumatology, 2011, Volume: 38, Issue:6 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Diclofenac; Etoricoxib; Female; Heart Failure; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Osteoarthritis; Peptide Fragments; Prospective Studies; Pyridines; Retrospective Studies; Risk Factors; Sulfones; Thrombosis; Treatment Outcome	2011
[Coronary risks with NSAID and coxibs. The end of hysteria]. MMW Fortschritte der Medizin, 2006, Nov-30, Volume: 148, Issue:48 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cause of Death; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Osteoarthritis; Peptic Ulcer; Prospective Studies; Pyridines; Randomized Controlled Trials as Topic; Risk; Sulfones; Thrombosis	2006

Article

Year

Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs.

The Journal of rheumatology, 2011, Volume: 38, Issue:6

Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Diclofenac; Etoricoxib; Female; Heart Failure; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Osteoarthritis; Peptide Fragments; Prospective Studies; Pyridines; Retrospective Studies; Risk Factors; Sulfones; Thrombosis; Treatment Outcome

2011

[Coronary risks with NSAID and coxibs. The end of hysteria].

MMW Fortschritte der Medizin, 2006, Nov-30, Volume: 148, Issue:48

Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cause of Death; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Osteoarthritis; Peptic Ulcer; Prospective Studies; Pyridines; Randomized Controlled Trials as Topic; Risk; Sulfones; Thrombosis

2006